Cannabis Law Report
DECEMBER 6, 2021
“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.
Project CBD
FEBRUARY 27, 2023
Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. 9,2 (2008): 164-73. It’s not a new idea. Current medical research and opinion vol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JANUARY 13, 2023
A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.
SMPL
MAY 26, 2020
And though a few outliers responded well to CBD alone, GW’s data showed that for relieving pain and inflammation, helping with sleep and alleviating seizures and spasms, most patients got the most benefit from an equal mix of CBD and THC — a drug the company called Sativex. The Stanleys told me their wait-list peaked at 15,000 names.
Cannabis Law Report
NOVEMBER 24, 2021
At the same time, the outlook on cannabis research data is largely positive. 2018 ; Frankhauser 2008 ). 2008 )—were difficult for any plant to compete with, especially one whose active constituents would not be revealed for another 30?years Data collection. This offers a more denotative approach to complement the data.
Cannabis Law Report
OCTOBER 29, 2019
The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
Expert insights. Personalized for you.
52 
Let's personalize your content